Article Text

Download PDFPDF
Paradox of amyotrophic lateral sclerosis and energy metabolism
  1. Rebekah M Ahmed1,2,
  2. Luc Dupuis3,
  3. Matthew C Kiernan1,2
  1. 1 Memory and Cognition Clinic, Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  2. 2 Brain and Mind Centre and Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
  3. 3 Fédération de médecine translationnelle, Université de Strasbourg, Inserm, UMR-S1118, Strasbourg, France
  1. Correspondence to Dr Rebekah M Ahmed, Memory and Cognition clinic, Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia; rebekahahmed{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Hypermetabolism may be linked to neurodegenerative processes in ALS

Amyotrophic lateral sclerosis (ALS) is a disease of paradoxes. Patients usually have little or no medical history and tend to be fit and athletic,1 2 yet undergo a rapid, unrelenting decline. Patients predominantly present with progressive weakness, with involvement of cortical motor neurons and as the disease progresses, patients develop denervation, muscle atrophy, decreased muscle mass and decreased free fat mass, all of which would be expected to decrease energy expenditure.3 Yet patients with ALS are consistently hypermetabolic, with increased resting energy expenditure evident in up to 50% of patients.4

Several variables have been hypothesised to contribute to this hypermetabolic state, including uncontrolled fasciculations, increased respiratory work and mitochondrial dysfunction,4 yet the exact mechanism remains to be elucidated. In their JNNP paper Steyn and colleagues5 aim to …

View Full Text


  • Contributors All authors drafted and reviewed the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Neurodegeneration
    Frederik J Steyn Zara A Ioannides Ruben P A van Eijk Susan Heggie Kathryn A Thorpe Amelia Ceslis Saman Heshmat Anjali K Henders Naomi R Wray Leonard H van den Berg Robert D Henderson Pamela A McCombe Shyuan T Ngo